Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

119.93 +1.16 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 750,529
Open 119.91
Bid (Size) 118.16 (2)
Ask (Size) 120.78 (1)
Prev. Close 118.77
Today's Range 117.67 - 120.76
52wk Range 76.53 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
From BioNTech SE
Via GlobeNewswire
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga

Performance

YTD
+6.75%
+6.75%
1 Month
+36.28%
+36.28%
3 Month
+52.14%
+52.14%
6 Month
+28.79%
+28.79%
1 Year
+6.37%
+6.37%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Forecasting The Future: 8 Analyst Projections For BioNTech
Via Benzinga
Market Whales and Their Recent Bets on BNTX Options
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
From BioNTech SE
Via GlobeNewswire
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Via Benzinga
Exposures COVID-19
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Via Benzinga
Exposures COVID-19
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Via Benzinga
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
From BioNTech SE
Via GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
Via Benzinga
Exposures COVID-19
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
Via Talk Markets
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
Via Benzinga
Exposures COVID-19
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.